These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19414670)

  • 1. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
    Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
    J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
    J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
    Lin J; Sinibaldi VJ; Carducci MA; Denmeade S; Song D; Deweese T; Eisenberger MA
    Urol Oncol; 2011; 29(6):670-5. PubMed ID: 19962920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
    Autio KA; Pandit-Taskar N; Carrasquillo JA; Stephenson RD; Slovin SF; Rathkopf DE; Hong C; Heller G; Scher HI; Larson SM; Morris MJ
    Cancer; 2013 Sep; 119(17):3186-94. PubMed ID: 23765638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Pastina I; Lorenzoni A; Cianci C; Federici F; Mazzarri S; Orlandini C; Francesca F; Selli C; Ricci S; Rubello D; Mariani G
    Nucl Med Commun; 2014 Jan; 35(1):88-94. PubMed ID: 24157942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
    Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
    J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.
    Menda Y; Bushnell DL; Williams RD; Miller S; Thomas MO
    Clin Nucl Med; 2000 Sep; 25(9):698-700. PubMed ID: 10983757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
    van Dodewaard-de Jong JM; de Klerk JM; Bloemendal HJ; van Bezooijen BP; de Haas MJ; Wilson RH; O'Sullivan JM
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1990-8. PubMed ID: 21792569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience.
    Suttmann H; Grgic A; Lehmann J; Zwergel U; Kamradt J; Gouverneur E; Pinkert J; Stöckle M; Kirsch CM; Nestle U
    Cancer Biother Radiopharm; 2008 Oct; 23(5):609-18. PubMed ID: 18999933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
    Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
    Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I trial of samarium-153-lexidronam complex for treatment of clinically nonmetastatic high-risk prostate cancer: first report of a completed study.
    Valicenti RK; Trabulsi E; Intenzo C; Lavarino J; Xu Y; Chervoneva I
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):732-7. PubMed ID: 20399029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
    Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
    Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
    Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E
    Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.
    Paravati AJ; Russo AL; Aitken C
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):506-10. PubMed ID: 20888141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
    Higano CS; Quick DP; Bushnell D; Sartor O
    Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
    Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
    Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
    Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
    J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
    Valicenti RK; Pugh SL; Trabulsi EJ; Sartor O; Ko EC; Girvigian MR; Rosenthal SA; Shaves ME; Hoffman-Censits JH; Schallenkamp J; Sandler HM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):695-701. PubMed ID: 29413282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Hudes G; Tagawa ST; Whang YE; Qi M; Qin X; Puchalski TA; Reddy M; Cornfeld M; Eisenberger M
    Invest New Drugs; 2013 Jun; 31(3):669-76. PubMed ID: 22828917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.